Europe Cardiac Surgical Devices Market - Innovations & Forecast 2026-2034

Europe Cardiac Surgical Devices Market Size and Forecast 2026-2034

Europe Cardiac Surgical Devices Market is expected to reach US$ 843.93 Million by 2034 from US$ 629.54 Million in 2025, with a CAGR of 3.31% from 2026 to 2034. The Europe cardiac surgical devices market is driven by rising cardiovascular disease prevalence, increasing demand for minimally invasive cardiac procedures, expanding elderly populations, growing healthcare investments, and continuous innovation in heart valves, surgical instruments, and advanced cardiac surgery technologies.

Europe Cardiac Surgical Devices Industry Overview

Cardiac surgical devices are specialized medical technologies used during surgical procedures to diagnose, repair, replace, or support structures of the heart and surrounding blood vessels. These devices include heart valves, annuloplasty rings, surgical ablation systems, ventricular assist devices, sternum fixation systems, and cardiopulmonary bypass equipment. They play a crucial role in treating conditions such as coronary artery disease, heart valve disorders, congenital heart defects, and heart failure. Advancements in minimally invasive surgery, robotic-assisted procedures, and transcatheter technologies have significantly improved patient outcomes. Growing demand for effective cardiovascular treatment continues to drive innovation and adoption of cardiac surgical devices across healthcare systems.

The European cardiac surgical devices market is experiencing sustained growth due to the increasing burden of cardiovascular diseases, rising geriatric population, and growing adoption of advanced cardiac procedures. Healthcare providers are increasingly utilizing innovative surgical technologies that improve procedural efficiency, reduce recovery times, and enhance clinical outcomes. The expansion of minimally invasive and transcatheter interventions is creating strong demand for next-generation cardiac surgical devices. Additionally, favorable healthcare infrastructure, increased awareness of early cardiovascular treatment, and ongoing investments in medical technology are supporting market development. Continuous product innovation by leading manufacturers further strengthens the adoption of advanced cardiac surgical solutions across Europe.

Recent Developments in Europe Cardiac Surgical Devices Market

• June 2026: Cardiawave commenced the European commercialization of Valvosoft(R), an innovative non-invasive ultrasound therapy for patients with severe symptomatic aortic stenosis, following its CE Mark approval in 2025. The system utilizes focused high-intensity ultrasound waves to improve native valve function without requiring surgical intervention or implantable devices, introducing a new treatment option for structural heart disease management across Europe.
• October 2025: Medtronic expanded its European cardiac surgery portfolio with the launch of the Penditure(TM) Left Atrial Appendage (LAA) Exclusion System after obtaining CE Mark certification. Designed for use during cardiac procedures in patients with atrial fibrillation, the device offers repositionable and redeployable functionality, enhancing procedural flexibility and supporting advancements in cardiac rhythm and structural heart therapies.
• January 2025: Medtronic secured CE Mark approval for its Harmony(TM) Transcatheter Pulmonary Valve (TPV) System throughout the European Union. Developed for patients with congenital heart disease experiencing severe pulmonary valve regurgitation, the minimally invasive system provides an alternative to traditional open-heart surgery and reinforces the growing adoption of transcatheter cardiac treatment approaches across Europe.

Growth Drivers for the Europe Cardiac Surgical Devices Market

Rising Adoption of Advanced Heart Valve Replacement Technologies

The growing prevalence of aortic stenosis and other valvular heart diseases is increasing demand for advanced cardiac surgical devices across Europe. Hospitals and cardiac centers are increasingly adopting innovative valve replacement technologies that offer improved durability, procedural efficiency, and long-term patient outcomes. The shift toward less invasive interventions and lifetime management of heart valve disease is encouraging healthcare providers to invest in next-generation surgical solutions. As Europe's aging population expands, the number of patients requiring valve replacement procedures continues to rise, creating significant opportunities for device manufacturers. Product innovation remains a key market catalyst.

In May 2024, Edwards Lifesciences launched the SAPIEN 3 Ultra RESILIA valve in Europe following CE Mark approval. The transcatheter valve incorporates RESILIA tissue technology designed to enhance valve durability and support long-term treatment outcomes for patients undergoing valve replacement procedures.

Increasing Demand for Enhanced Surgical Efficiency and Patient Recovery

European healthcare systems are increasingly focused on improving surgical efficiency, reducing complications, and accelerating patient recovery following cardiac procedures. This trend is driving adoption of advanced surgical instruments and tissue management technologies that enable precise dissection, vessel sealing, and improved intraoperative performance. Hospitals are seeking solutions that support shorter procedure times and better clinical outcomes while optimizing resource utilization. As cardiac surgeries become more complex, surgeons are relying on innovative technologies that enhance procedural control and safety.

Reflecting this trend, Olympus introduced THUNDERBEAT II in Europe, the Middle East, and Africa in October 2025. The next-generation hybrid energy device offers enhanced vessel sealing, faster tissue dissection, and improved ergonomic design, helping surgeons perform complex cardiovascular and thoracic procedures more efficiently.

Expansion of Cardiac Surgery Innovation and Device Modernization

Technological advancements in cardiac surgery are transforming treatment approaches across Europe. Manufacturers are investing heavily in devices that improve surgical precision, simplify implantation procedures, and support long-term patient management. Growing demand for innovative cardiac solutions is encouraging healthcare providers to upgrade existing surgical platforms and adopt modern technologies. The increasing emphasis on patient-centered care and improved postoperative outcomes is further accelerating market growth. A notable development occurred in October 2024, when Medtronic launched the Avalus Ultra(TM) surgical aortic valve in Western Europe. Designed to facilitate ease of implantation and support long-term valve management, the device provides enhanced visibility and improved hemodynamic performance, reflecting the industry's ongoing focus on innovation in cardiac surgery.

Challenges in the Europe Cardiac Surgical Devices Market

High Cost of Advanced Cardiac Surgical Devices

Advanced cardiac surgical devices often involve substantial acquisition and implementation costs. Technologies such as transcatheter heart valves, ventricular assist devices, and specialized surgical systems require significant financial investment from healthcare providers. Budget constraints within certain European healthcare systems can delay adoption of innovative technologies, particularly in smaller hospitals. Additionally, maintenance expenses, training requirements, and procedural costs may increase the overall financial burden. These factors can limit access to advanced cardiac interventions despite demonstrated clinical benefits. Cost-containment initiatives within public healthcare systems may further influence purchasing decisions and slow the adoption of premium surgical technologies across some European markets.

Stringent Regulatory and Reimbursement Requirements

Manufacturers operating in Europe must navigate complex regulatory frameworks and reimbursement processes before introducing new cardiac surgical devices. Compliance with Medical Device Regulation (MDR) requirements often involves extensive clinical evidence, documentation, and post-market surveillance activities. The approval process can increase development timelines and costs. Furthermore, reimbursement policies vary significantly across European countries, creating challenges for market access and commercial expansion. Delays in obtaining reimbursement approval may limit physician adoption and patient access to innovative therapies. These regulatory and reimbursement complexities remain important barriers for companies seeking to expand their presence in the European cardiac surgical devices market.

France Cardiac Surgical Devices Market

France represents a significant market for cardiac surgical devices due to its advanced healthcare infrastructure, strong cardiovascular care network, and increasing demand for innovative cardiac procedures. Hospitals and specialized cardiac centers are adopting advanced surgical technologies to improve treatment outcomes for patients with heart valve disease, coronary artery disease, and heart failure. Government support for healthcare modernization and access to specialized cardiovascular care further supports market growth. According to the French National Institute of Statistics and Economic Studies (INSEE), 22% of France's population was aged 65 years or older in 2024. The country's aging demographic profile contributes to a growing burden of cardiovascular diseases, creating sustained demand for cardiac surgical procedures and associated medical devices.

Germany Cardiac Surgical Devices Market

Germany is one of Europe's largest cardiac surgical devices markets, supported by its advanced healthcare infrastructure, strong reimbursement system, and extensive network of specialized cardiovascular centers. The country continues to adopt innovative cardiac surgical technologies aimed at improving procedural efficiency and patient outcomes. Growing prevalence of cardiovascular diseases and increasing utilization of minimally invasive cardiac interventions are driving demand for heart valves, surgical ablation systems, and other advanced cardiac devices. Germany also remains a leading center for medical technology innovation and clinical research across Europe. According to the German Federal Statistical Office (Destatis), by 2035, one-quarter of Germany's population is projected to be aged 67 years or older, highlighting the growing elderly population that is more susceptible to cardiovascular conditions. This demographic trend is expected to sustain long-term demand for cardiac surgical procedures and associated medical devices.

Italy Cardiac Surgical Devices Market

Italy's cardiac surgical devices market is expanding due to increasing cardiovascular disease prevalence, an aging population, and growing access to specialized cardiac care services. Hospitals across the country are investing in advanced surgical technologies to improve outcomes for patients requiring valve replacement, coronary artery bypass surgery, and other complex cardiac procedures. The adoption of minimally invasive techniques is also contributing to market growth. Italy's healthcare system continues to prioritize cardiovascular disease management through improved diagnostic and treatment capabilities. According to the Italian National Institute of Statistics (ISTAT), individuals aged 65 years and above account for nearly one-quarter of Italy's population, making it one of Europe's oldest populations. This demographic trend supports long-term demand for cardiac surgical interventions and related devices.

Spain Cardiac Surgical Devices Market

Spain is witnessing increasing demand for cardiac surgical devices due to rising cardiovascular disease incidence, growing healthcare investments, and expanding access to specialized cardiac treatment centers. The country's healthcare providers are increasingly adopting innovative surgical technologies that enhance procedural precision and patient outcomes. Demand for heart valve replacement systems, surgical instruments, and minimally invasive cardiac solutions continues to grow. Spain also benefits from ongoing modernization of healthcare facilities and increasing focus on cardiovascular disease prevention and management. According to the Spanish National Statistics Institute (INE), life expectancy in Spain remains among the highest in Europe, exceeding 83 years, contributing to a larger elderly population at risk of cardiovascular conditions. This demographic factor supports continued growth in demand for cardiac surgical devices.

Europe Beating Heart Surgery Systems Market

The Europe beating heart surgery systems market represents an important segment of the cardiac surgical devices industry, driven by increasing adoption of off-pump coronary artery bypass (OPCAB) procedures. These systems enable surgeons to perform cardiac surgery while the heart continues to beat, eliminating the need for cardiopulmonary bypass in selected patients. The approach is associated with reduced complications, shorter hospital stays, and faster recovery times, making it increasingly attractive to healthcare providers. Growing prevalence of coronary artery disease and rising demand for minimally invasive cardiac procedures are supporting market growth. Technological advancements in stabilization devices, positioning systems, and surgical instruments are further improving procedural outcomes. As European hospitals continue to prioritize patient-centered care, demand for beating heart surgery systems is expected to increase.

Europe Congenital Heart Defects Market

The Europe congenital heart defects market plays a significant role in the cardiac surgical devices industry due to the ongoing need for specialized surgical interventions and long-term cardiac care. Congenital heart defects encompass structural abnormalities of the heart present at birth, many of which require corrective surgery or device-based treatment. Advances in pediatric cardiac surgery, diagnostic imaging, and interventional cardiology have significantly improved survival rates and treatment outcomes. Growing awareness of early diagnosis and increasing access to specialized cardiac centers across Europe are supporting market development. The demand for surgical valves, closure devices, grafts, and other cardiac surgical technologies remains strong. Continuous innovation in minimally invasive procedures and pediatric cardiac care is further enhancing treatment options for patients with congenital heart conditions.

Europe Hospitals Market

Hospitals constitute the largest end-user segment within the Europe cardiac surgical devices market, serving as primary centers for complex cardiovascular procedures and advanced cardiac care. Major hospitals across the region are increasingly investing in innovative surgical technologies to improve procedural precision, patient safety, and clinical outcomes. The growing burden of cardiovascular diseases and rising demand for heart valve replacement, coronary artery bypass surgery, and structural heart interventions are driving utilization of cardiac surgical devices in hospital settings. Additionally, the expansion of hybrid operating rooms and specialized cardiovascular departments is supporting adoption of advanced surgical equipment. European hospitals also play a critical role in clinical research and evaluation of new cardiac technologies. Continued healthcare modernization and infrastructure investments are expected to strengthen demand for cardiac surgical devices across hospital networks.

Research Methodology of the Europe Cardiac Surgical Devices Market

Step 1: Market Definition and Scope

The Europe Cardiac Surgical Devices Market was first defined according to the devices and equipment used during open-heart, minimally invasive, and other cardiac surgical procedures.

The scope included:

• Heart-lung machines
• Cardiopulmonary bypass systems
• Cardiac surgery cannula
• Heart valve repair and replacement devices
• Annuloplasty rings
• Cardiac surgical staplers
• Aortic repair devices used in surgery
• Surgical ablation systems, etc.

The scope was further divided into capital equipment, implantable devices, reusable instruments, and disposable surgical products, as each category had different utilization patterns, replacement cycles, and pricing structures.

Step 2: Estimate Cardiac Surgery Procedure Volume

The estimation was initiated by determining the number of cardiac surgical procedures performed across European countries.

Major procedure categories included:

• Coronary artery bypass grafting (CABG)
• Heart valve repair
• Heart valve replacement
• Aortic surgery
• Congenital heart surgery
• Cardiac ablation surgery
• Transplantation
• Mechanical circulatory support procedures
• Other cardiac surgical procedures

The European Association for Cardio-Thoracic Surgery (EACTS) Adult Cardiac Database was used as an important source because it collected cardiac surgical intervention data from participating European hospitals and national registries.

The European Society of Cardiology (ESC) Atlas was also used to obtain country-level cardiac surgery indicators. For example, its 2024 data reported CABG procedure rates for numerous European countries, including Germany, France, the United Kingdom, Spain, the Netherlands, Poland, Sweden, and others.

Step 3: Calculate Device Utilization per Procedure

After estimating procedure volumes, the number of devices and consumables required per procedure was determined.

For disposable products, the calculation was:

Annual Cardiac Surgery Procedures X Average Device Utilization per Procedure

Device utilization was calculated separately because different procedures required different combinations of products.

For example, a CABG procedure could require cardiopulmonary bypass-related products, cannula, surgical sutures, retractors, blood-conservation products, and other consumables, whereas valve surgery could require additional valve-specific surgical products.

Step 4: Establish Average Selling Price

The average selling price was then determined separately for each device category.

Pricing was differentiated according to:

• Device type
• Procedure
• Country
• Public versus private hospital
• Capital equipment versus disposable
• Implantable versus non-implantable product
• Manufacturer versus distributor pricing

The weighted ASP was calculated as:

Weighted ASP = Σ (Product Volume X Product ASP) ÷ Total Product Volume

Manufacturer or distributor selling prices were used where possible rather than hospital procedure charges, since hospital charges could include physician services, facility costs, medicines, and other healthcare expenses outside the device market.

Step 5: Build the Bottom-Up Market Estimate

The bottom-up approach was used as the primary market-estimation method.

The core calculation was:

Europe Cardiac Surgical Devices Market = Σ (Cardiac Surgery Procedures X Device Utilization per Procedure X ASP) + Capital Equipment Sales

The calculation was performed separately by:

• Device category
• Cardiac procedure
• Country
• Hospital type
• Capital versus disposable products, etc.

The country-level estimates were subsequently aggregated to calculate the overall European market.

Step 6: Estimate Capital Equipment Separately

Capital equipment such as heart-lung machines, cardiopulmonary bypass systems, perfusion equipment, surgical visualization systems, and other reusable equipment was estimated separately.

The calculation considered:

Installed Base X Annual Replacement Rate X Average Equipment Price

plus:

New Cardiac Surgery Centers/Operating Rooms X Equipment Requirement X Average Equipment Price

Replacement demand was therefore separated from new installations to prevent the equipment market from being overstated.

Step 7: Procedure-Specific Device Modelling

The market was then modelled separately for the major cardiac surgical procedures.

CABG

CABG procedure volumes were multiplied by the average value of cardiac surgical devices and consumables used during each procedure.

The ESC Atlas provided country-level CABG rates and reported a Europe-wide 2024 rate of 257.6 CABG procedures per million people.

Valve Surgery

Valve repair and replacement procedures were estimated separately because they required different surgical instruments and implantable products.

The model incorporated surgical valve procedures, repair systems, annuloplasty products, surgical accessories, and associated consumables.

Aortic Surgery

Aortic procedures were modelled using procedure volumes and the average device expenditure associated with surgical aortic repair.

Mechanical Circulatory Support

Mechanical circulatory support products were estimated separately because their unit prices and utilization were substantially different from conventional surgical consumables. The ESC Atlas separately tracked ventricular assist-device implantations, while EACTS maintained the EUROMACS registry for mechanical circulatory support.

Step 8: Hospital and Infrastructure Validation

The number of cardiac surgery hospitals and operating facilities was used to validate the potential installed base of cardiac surgical equipment.

The ESC Atlas reported 1.20 hospitals with cardiac surgery per million people for Europe in 2024, with country-level differences across Germany, France, Spain, the United Kingdom, and other European markets.

The analysis therefore considered:

• Number of cardiac surgery hospitals
• Number of cardiac operating rooms
• Number of cardiac surgeons
• Annual procedures per hospital
• Equipment installed per hospital
• Equipment replacement cycle, etc.

This approach helped validate the capital-equipment portion of the market.

Step 9: EACTS and Clinical Registry Validation

The bottom-up estimate was cross-checked against EACTS cardiac-surgery databases.

The EACTS Adult Cardiac Database had collected anonymized cardiac surgical data from European participating centres and national registries. As of August 2026, it contained almost 100,000 patient records from 24 hospitals across 11 countries, covering procedures performed between 2010 and 2025.

These data were used to validate:

• Procedure volumes
• Procedure mix
• Hospital activity
• Changes in surgical practice
• Country-level trends

Because the EACTS database did not cover every European cardiac-surgery centre, it was used as a validation source rather than as the sole source for total European procedure volume.

Step 10: Manufacturer-Level Validation

The estimated market was then validated using manufacturers of cardiac surgical devices and equipment.

The analysis considered:

• Cardiac surgery revenue
• Europe revenue
• Product-specific revenue
• Heart-lung machine installations
• Surgical-device sales
• Valve-related surgical products
• Perfusion products
• Surgical instrument sales
• New product launches
• Distributor networks
• Hospital contracts
• Installed equipment base

Where manufacturers reported only broader cardiovascular or medical-device revenues, the cardiac surgical component was separated using product portfolios and geographic exposure.

Step 11: Reimbursement and Healthcare Expenditure Validation

European healthcare reimbursement and hospital expenditure data were used to validate procedure volumes and device expenditure.

The analysis considered:

• National reimbursement systems
• Hospital budgets
• Procedure reimbursement
• Public healthcare expenditure
• Private healthcare spending
• Device reimbursement
• Implant reimbursement
• Hospital procurement prices

This was particularly important because the price paid by a hospital for a device could differ significantly from the total reimbursed amount for the associated cardiac procedure.

Step 12: Top-Down Validation

A top-down approach was then applied as an independent validation.

The model was structured as:

European Cardiovascular Devices Market X Cardiac Surgical Device Share = Cardiac Surgical Devices Market

A second approach could have used:

European Cardiac Surgery Expenditure X Device Expenditure Share = Cardiac Surgical Devices Market

The cardiac surgical-device share was derived from manufacturer revenues, hospital procurement data, procedure expenditure, product portfolios, and industry statistics rather than from an arbitrary assumption.

Step 13: Import-Export and Supply-Side Validation

International trade data were used as an additional supply-side cross-check.

The apparent domestic supply was calculated as:

Domestic Production + Imports - Exports = Apparent Domestic Supply

Relevant trade classifications were reviewed for:

• Surgical instruments
• Cardiopulmonary bypass equipment
• Heart-lung machines
• Surgical devices
• Implantable cardiac products
• Other cardiovascular surgical equipment

Trade statistics were treated as a supporting validation source because individual customs classifications could contain products outside the precise cardiac-surgical-device scope.

Step 14: Third Validation and Market Triangulation

The final market estimate was triangulated through three independent approaches:

A. Bottom-Up Approach

Cardiac surgery procedures X device utilization X ASP + capital equipment.

B. Top-Down Approach

Cardiovascular/medical-device expenditure X cardiac surgical-device share.

C. Supply-Side Approach

Manufacturer revenue + hospital procurement + imports - exports + installed equipment base.

The three estimates were compared and discrepancies were investigated based on:

• Differences in market definitions
• Capital equipment versus consumables
• Implantable versus non-implantable products
• Manufacturer versus hospital prices
• Procedure overlap
• Cross-border procurement
• Replacement cycles
• Distributor margins
• Products used in both cardiac and non-cardiac surgery

The final market estimate was established after reconciling these differences rather than simply averaging the three calculations.

Step 15: Country-Level Market Estimation

The European market was estimated separately for major countries before being aggregated.

The country model incorporated:

• Population
• Cardiac surgery procedure volume
• CABG procedures
• Valve surgery
• Aortic surgery
• Number of cardiac surgery hospitals
• Healthcare expenditure
• Cardiac surgeon availability
• Device penetration
• Equipment installed base
• Replacement rates
• Device pricing
• Public/private hospital activity

The calculation was structured as:

Germany + France + United Kingdom + Italy + Spain + Netherlands + Switzerland + Belgium + Nordics + Poland + Rest of Europe = Europe Cardiac Surgical Devices Market

Country-level modelling was important because cardiac surgery volumes and healthcare procurement structures differed significantly across Europe.

Step 16: Historical Market Estimation

Historical market values were estimated using historical cardiac surgery volumes, device utilization, ASPs, equipment installations, replacement cycles, reimbursement information, and manufacturer revenues.

Historical ASPs were applied to the relevant historical years instead of using current prices retrospectively.

Historical procedure trends were also incorporated to account for changes in:

• CABG utilization
• Valve surgery
• Minimally invasive cardiac surgery
• Surgical ablation
• Aortic surgery
• Mechanical circulatory support
• Cardiac surgery technology

Step 17: Market Forecasting

The future Europe Cardiac Surgical Devices Market was forecast using expected cardiac surgery volumes, device utilization, replacement demand, technology adoption, and ASP development.

The basic forecasting formula was:

Future Market = Future Cardiac Surgery Procedures X Future Device Expenditure per Procedure + Future Capital Equipment Demand

The forecast incorporated:

• Aging European population
• Cardiovascular disease burden
• Growth in valve disease treatment
• Cardiac surgery technology adoption
• Minimally invasive cardiac surgery
• Robotic and advanced surgical systems
• Replacement of aging equipment
• Hospital infrastructure investment
• Development of specialized cardiac centers
• Adoption of advanced perfusion technologies
• Mechanical circulatory support

Procedure forecasts were adjusted country by country rather than applying one uniform European growth rate.

Core Market Formula

Europe Cardiac Surgical Devices Market = Σ [Cardiac Surgery Procedures X Device Utilization per Procedure X ASP] + Capital Equipment Sales

The bottom-up procedure-based approach was used as the foundation, while EACTS cardiac-surgery data, ESC procedure statistics, hospital infrastructure, manufacturer revenues, reimbursement information, and trade statistics were used as independent validation layers. EACTS and ESC data were particularly useful for validating European cardiac-surgery activity and country-level procedure differences.

Europe Cardiac Surgical Device Market Segments:

Product Type

• Beating Heart Surgery Systems
• Cardiopulmonary Bypass Equipment
• Cardiac Ablation Devices
• Perfusion Disposable

Application

• Congential Heart Defects
• Cardiac Arrthymia
• Coronary Heart Disease
• Congestive Heart Failure
• Others

End Users

• Hospitals
• Ambulatory Surgical Centers
• Others

Countries

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• Boston Scientific Corporation
• Edwards Lifesciences
• Cardinal Health Inc.
• Medtronic PLC
• GE Healthcare
• LivaNova PLC
• Terumo Corporation